Upon ex vivo testing of the PD-1 Abs in excised and dissociated human tumor biopsies that mimic the cellular composition of the tumor microenvironment, we observed a difference in kinetics and intensity of IFN pathway gene activation in response to treatment with toripalimab and pembrolizumab. The gene discussed is IFNA1; the disease is neoplasm.